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Aim: Can gene expression profiling be used to identify patients with T1–T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population
in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested
(n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively. Results:
Patients 55–64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4.9% and
1.6%. Class 2B (high-risk) patients had SLN positivity rates of 30.8% and 11.9%. Melanoma-specific survival
was 99.3% for patients ≥55 years with class 1A, T1–T2 tumors and 55.0% for class 2B, SLN-positive, T1–T2
tumors. Conclusion: The 31-gene expression profile test identifies patients who could potentially avoid
SLN biopsy.
First draft submitted: 10 December 2018; Accepted for publication: 14 January 2019; Published online:
29 January 2019
Keywords: biomarker • gene expression profiling • melanoma • prognosis • sentinel lymph node biopsy

Cutaneous melanoma (CM) has one of the fastest rising incidence rates of all malignancies in the USA, with more
than 91,270 new cases and 9000 deaths expected in 2018 [1]. Of these, more than 70,000 patients are diagnosed
with stage I or II (localized) disease as defined by the American Joint Committee on Cancer (AJCC) staging
system [1,2]. Patients with early stage melanoma (i.e., AJCC stage I–II) are regarded as having a good prognosis
according to population-based risk estimates. However, due to the greater number of individuals within these
earlier stages, more than twice as many people diagnosed with early stage disease will ultimately die of melanoma
compared with those diagnosed with stage III melanoma [3,4].
Per guidelines, a sentinel lymph node biopsy (SLNB) procedure should be considered for all patients with
stage T1b melanoma and above, along with a subset of T1a patients with high-risk features [5,6]. Patients with a
positive SLN are at substantially increased risk for distant metastatic disease and death. The Multicenter Selective
Lymphadenectomy Trial (MSLT-I) reported that the SLNB procedure provides prognostic information, but does
not appear to improve melanoma-specific survival (MSS), although a subset of patients with intermediate thickness
melanoma and microscopic nodal involvement showed improved survival at 10 years post-randomization compared
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with patients in the observation arm who experienced nodal recurrence [4]. Recently, the MSLT-II study also showed
no survival benefit associated with completion lymphadenectomy in SLN positive patients [7]. For patients able to
tolerate adjuvant therapy, identification of SLN positive disease enables use of immunotherapy or targeted therapy
in the adjuvant setting [8–11]. Overall, the likelihood of a positive SLN is reported to be 15–20% in intermediate
thickness tumors [4,12,13], but this varies widely depending on tumor and patient features [14–17]. A <5% likelihood
for a positive SLN is currently recommended by the National Comprehensive Cancer Network guidelines (NCCN
v3.2018, July 2018) as a threshold for not performing this procedure, while recommending consideration of SLNB
if the risk is 5–10%, and offering SLNB if the risk is above 10% [6].
The decision to perform SLNB is not without risk. While the rates are low (5–10%), the SLNB procedure can
be associated with complications such as pain, bleeding, allergic reactions to the dye, wound infection, seromas,
deep vein thrombosis, nerve damage and edema [7,18,19]. Additionally, the procedure requires a dedicated team
that includes nuclear medicine physicians, surgeons and pathologists [20–22] and in most cases involves general
anesthesia. Therefore, combined with associated surgical and pathology fees, it has been estimated that the cost of
an SLNB can be ten-times that of a basic wide local excision alone, and the cost to identify a single positive SLN
in the population of patients with thin tumors can approach 1 million dollars [23]. Therefore, strategies that can
help reduce surgical risks and complications and potentially reduce healthcare system costs are necessary, especially
in populations with low yield from SLNB procedures.
A 31-gene expression profile (31-GEP) that estimates a CM patient’s risk for metastatic disease has been
previously reported [24–28]. The test uses a radial basis machine algorithm to classify patients into four risk groups
with increasing probability of recurrence: low (class 1A), intermediate (class 1B or 2A) or high (class 2B) risk for
developing metastasis within 5 years of diagnosis. Prior studies had shown that patients with a class 1 (class 1A or
1B) profiles have lower rates of SLN positivity when compared with class 2 (class 2A or 2B) patients, albeit with
a positive rate higher than the 5% threshold currently used to determine SLNB eligibility [26,29]. To determine if
the 31-GEP test could identify a population with <5% likelihood of a positive SLN, we performed modeling in
a large retrospective cohort. The current study reports validation of the use of the 31-GEP test to identify patients
with low probability of a positive SLN in a defined patient population from a large prospective cohort.
Methods
Evaluation of SLN prediction by GEP test

Rules-based and regression analyses to determine significant predictors of SLN positivity and identification of
optimal cut-offs to define a population in which gene expression could better predict SLNB results were performed.
This evaluation was done using the normalized gene expression data and clinicopathologic variables for 946 archived
tumor samples collected as part of the institutional review board (IRB)-approved protocol for initial validation
of the 31-GEP test. Evaluation to determine if the current algorithm in the 31-GEP could be improved for the
purposes of SLN positivity risk prediction was also performed. We employed predictive modeling with multiple
machine learning approaches, including neural networks, self-organizing maps, support vector machine and treebased models, using gene expression alone and gene expression with clinicopathologic features. Additional details
regarding the evaluation of alternative algorithms for SLN guidance and results are described in the Supplementary
Methods, Results and Supplementary Figure 1.
Patient cohorts

Following determination of the optimal cut-offs for selecting a population in which the test could identify patients
with a low probability of a positive SLN, validation of this approach was performed in two prospectively collected
cohorts from 26 dermatologic or tertiary care centers. Cohort 1 consisted of 584 patients enrolled in one of two
prospective, ongoing registry studies and a prospective clinical utility study [30,31], all of which had IRB-approved
study protocols. Participating centers in these registry studies include dermatology practices and tertiary care centers.
Cohort 2 included 837 cases from surgical tertiary care centers who tested patients between 2014 and 2017, for
which clinical data and SLNB status were collected under IRB-approved research protocols established at each
center. Analyses were performed for all patients in these cohorts as well as for the subset that were T1b and above
(eligible) or T1a patients who had the procedure performed (assessed). In order to represent the intended use
population and to provide better estimates of SLN positivity rates for each genomic class and age group, results
from the two pooled cohorts are also shown. To determine the clinical outcome impact of using this approach to
determine whether to do an SLNB or not, long-term clinical outcome data were assessed from 690 patients who
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Table 1. Demographics and clinical characteristics of two prospectively collected validation cohorts.
Clinical feature

Cohort 1 (n = 584)

Cohort 2 (n = 837)

p-value

61 (18–100)

63 (12–101)

0.05

– Median (range)

1.2 (0–18)

1.16 (0–60)

0.21

Ulceration present

19% (103/554)†

25% (204/819)‡

0.006

Mitotic rate ≥1/mm2

59% (342/584)

64% (534/836)

0.043

Node status positive

14% (59/417)§

12% (85/701)¶

0.33

– T1

44% (258/584)

42% (355/837)

0.67

– T2

31% (183/584)

32% (269/837)

– T3

17% (101/584)

17% (139/837)

– T4

7% (42/584)

9% (74/837)

GEP class 2

24% (143/584)

29% (245/837)

Age (years):
– Median (range)
Breslow depth (mm):

T Stage:

0.046

Cohort 1 is comprised of patients enrolled in two prospective registry studies from dermatology and surgical practices; cohort 2 is comprised of prospectively
tested patients at surgical tertiary care centers. p-values for dichotomous variables represent Pearson’s  2 tests; p-values for the continuous variables of
age and Breslow depth represent Wilcoxon F tests.
† 30 cases did not report whether ulceration was present or absent.
‡ 18 cases did not report whether ulceration was present or absent.
§ 167 cases did not undergo sentinel lymph node biopsy.
¶ 136 cases did not undergo sentinel lymph node biopsy.
GEP: Gene expression profile.

had more than 5 years of follow-up or a documented recurrence of melanoma [24,25,27,32]. These patients represent
a subset of the 946 patient retrospective cohort described above.
GEP testing

The 31-GEP test (DecisionDx-Melanoma, Castle Biosciences, Inc., TX, USA) was performed on all of the primary
melanoma cases in this study, and the result was correlated with tumor, clinical and nodal outcomes, as noted above.
All GEP testing was performed in the Castle Biosciences Inc. CAP-accredited and CLIA-certified laboratory. The
development and validation of the 31-GEP test have been previously described [24–30].
Statistical analysis

All statistical analysis was performed using the statistical analysis package R, version 3.3.2. A two-sided p-value <0.05
was considered statistically significant. Pearson’s χ2 and Wilcoxon F tests were used for comparing demographic and
clinical categorical variables between patient groups. Fisher’s exact tests were used for SLN positivity comparisons.
Survival curves were estimated using the Kaplan–Meier method and compared by log-rank tests. End points for
survival analysis included MSS, overall (OS), distant metastasis-free (DMFS) and recurrence-free (RFS) survival.
MSS outcomes required confirmed mortality resulting from melanoma, OS included patients who died from
melanoma or other/unknown causes, DMFS included any recurrence beyond the regional nodal basin and RFS
included any recurrence from melanoma excluding SLN positivity. For RFS and DMFS, a patient was considered
censored if the patient was either lost to follow-up or had experienced a death event at the indicated time.
Results
Validation cohort demographics

Clinical demographics for validation cohort 1 and cohort 2 indicate these patient groups reflect the general
population of melanoma patients (Table 1) [12,13], with median ages of 61 and 63 years, respectively, and SLN
positive rates of 14 and 12%, respectively. While ulceration rates, mitosis and GEP class were statistically different
between cohorts 1 and 2 (p = 0.006, p = 0.043 and p = 0.046, respectively), both cohorts are similar in the
distribution of T stages, node positivity and Breslow thickness, reflecting the target population for use of the GEP
test for guiding SLNB.
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Table 2. Sentinel lymph node positivity rates in the independent and combined validation cohorts for all T1/T2 patients
in the study.
Patient age group

T1/T2

SLN positivity (class
1A)

95% CI (class 1A)

SLN positivity (class
2B)

95% CI (class 2B)

All

441

⬍55

158

p-value

4.2% (14/330)

2.3–7.0%

7.4% (2/27)

1.0–24%

0.35

6.8% (8/118)

3.0–12.9%

0.0% (0/5)

0–52%

⬎0.99

Cohort 1

55–64

111

5.7% (5/88)

1.9–12.8%

20% (1/5)

1.0–72%

0.29

≥65

172

0.8% (1/124)

0–4.4%

5.9% (1/17)

0–29%

0.23

All

624

4.8% (22/460)

3–7.2%

24.5% (13/53)

13.8–38.3%

⬍0.001

⬍55

212

8.2% (14/171)

4.5–13.4%

30% (6/20)

11.9–54.3%

0.009

Cohort 2

55–64

136

4.3% (4/94)

1.2–10.5%

37.5% (3/8)

8.5–75.5%

0.01

≥65

276

2.1% (4/195)

0–5.2%

16% (4/25)

4.5–36.1%

0.007

Combined cohorts 1 and 2
All

1065

4.6% (36/790)

3.2–6.3%

18.8% (15/80)

10.9–29%

⬍0.001

⬍55

370

7.6% (22/289)

4.8–11.3%

24.0% (6/25)

9.4–45.1%

0.02

55–64

247

4.9% (9/182)

2.3–9.2%

30.8% (4/13)

9.1–61.4%

0.006

≥65

448

1.6% (5/319)

0.5–3.6%

11.9% (5/42)

4.0–25.6%

0.003

Data in this table are also represented in Figure 1A. p-values reflect two-sided statistical significance from Fisher’s exact tests comparing class 1A to 2B.
SLN: Sentinel lymph node.

SLN probability in GEP subclasses

The aim of this study was to evaluate whether the GEP test could identify patients with low risk for SLN positivity in
the T1–T2 melanoma population who currently would be considered for SLNB based on guidelines. Understanding
that a patient has a very low risk for a positive SLN could inform decisions on the SLNB procedure. These include
patients with T1a melanomas, who may be considered for SLNB based on adverse features, including uncertain
microstaging, lymphovascular invasion, elevated mitotic rate and others [6]. Of note, the majority of the patients
with T1a melanoma in this study were managed at surgical centers and were thus being considered for SLNB;
34% of the T1a cases in this study underwent SLNB. We also evaluated performance in a narrower population
that included only patients who had the SLNB procedure (assessed) or were T1b and above (eligible). Of the 1421
total patients included in the validation study, 79% had a SLNB performed. Overall, 1065 had T1 or T2 thickness
(i.e., ≤2 mm thick) tumors. As shown in Table 2, the SLN positivity rate for all patients with T1–T2, class 1A
tumors was 4.6% (4.2% for cohort 1 and 4.8% for cohort 2), while the SLN positivity rate for patients with
T1–T2, class 2B tumors was 18.8% (7.4% for cohort 1 and 24.5% for cohort 2; p < 0.001 for class 1A vs class 2B
in the combined cohort). Patients with class 1B–2A showed intermediate SLN positivity rates (Figure 1A) .
Based on a Loess model fit to the risk of SLN positivity with age, the ages of 55 and 65 were identified as
inflection points indicating differential risk. As such, patients in the combined cohort were binned into three
groups for analysis: <55, 55–64 and ≥65 years old. Patients with GEP class 1A, T1–T2 tumors in age groups
<55, 55–64 or ≥65 years had SLN positivity rates of 7.6, 4.9 and 1.6%, respectively, compared with 24.0, 30.8
and 11.9% for class 2B (p < 0.02 for class 1A vs class 2B in each age group, Table 2 & Figure 1A). As a group,
patients ≥55 years with T1–T2 melanoma and a class 1A result had a SLN positivity rate of 2.8% while those with
a class 2B result had 16.4% SLN positivity. Similar results were obtained when the analysis was performed only
with patients who were eligible for a SLNB and/or had the procedure performed (n = 838; Table 3, Figure 1B,
Supplementary Table 1).
Survival rates associated with SLN guidance by gene expression profiling

Next, we estimated the survival outcomes of patients ≥55 years old with class 1A, T1–T2 tumors, the target
population that would not undergo SLNB. Long-term clinical outcomes from patients previously reported in three
clinical validity studies for the 31-GEP test [24,25,27] were used for survival analyses. Long-term outcome (survival
rate) comparisons of the 690-patient cohort are comparable to that observed with the recently compiled AJCC 8th
edition database (MSS for AJCC 8th edition stage I = 98%, stage II = 90% and stage III = 77%, compared with
MSS for stage I = 99%, stage II = 91% and stage III = 76% for the 690-sample) [2,32]. As shown in Figure 2A,
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30
25
20
15
10
5
0
All ages
Class 1A

SLNB positivity (%)

35

<55

55–64

Class 1B/2A

≥65
Class 2B

T1/T2 SLNB eligible or assessed

30
25
20
15
10
5
0
All ages
Class 1A

<55

55–64

Class 1B/2A

≥65
Class 2B

Figure 1. Sentinel lymph node positivity rate according to gene expression profile, subclass for T1/T2 staged
patients of all ages, and stratified in age groups <55, 55–64 or ≥65 years. (A) Clinical sentinel lymph node positivity
rate for T1 or T2 cases within the validation cohort (n = 1065), patients <55 years old (n = 370), between 55 and 64
(n = 247) and ≥65 (n = 448). These data are also represented in Table 2. (B) Clinical sentinel lymph node positivity rate
for T1 or T2 patients who were eligible for or assessed by SLNB. All ages within the validation cohort (n = 838),
patients <55 years old (n = 302), between 55 and 64 (n = 189) and ≥65 (n = 347) are shown for this eligible or assessed
population. These data are also presented in Table 3. In both panels, positivity rates are reported for each GEP test
result: class 1A (blue triangle), class 1B/2A (gray square), class 2B (red circle) results.
SNLB: Sentinel lymph node biopsy.

5-year MSS, OS, DMFS and RFS rates were high for GEP class 1A, but were lower for SLN negative GEP class
2B patients, and for SLN positive GEP class 2B patients (p < 0.05 for class 1A vs class 2B and SLN negative for
all end points, p < 0.001 for class 1A vs class 2B and SLN positive for all end points). Comparable results were
observed when patients of all ages were evaluated (Figure 2B).
Potential impact of gene expression profiling on SLNB rates

If patients with T1–T2, class 1A tumors with a risk of SLN positivity below 5% would not undergo SLNB, an
increase in the yield of positive SLNs and a reduction of the number of SLNB procedures performed would be
observed. In this prospective cohort of 1421 patients, if patients 55–64 years with class 1A, T1–T2 tumors did
not undergo SLNB, the positive SLN yield in patients in this age group with T1–T4 melanoma would increase
from 13.3 to 18.6%, while reducing SLNB procedures by 46.5% (by 66.7% in the T1–T2 population alone).
The positive SLN yield in patients ≥65 years with T1–T4 melanoma would increase from 8.7 to 13.6%, with a
reduction in SLNBs by 42.8% (by 65.1% in the T1–T2 population alone).
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Table 3. Sentinel lymph node positivity rates in the independent and combined cohorts for all patients in the study who
were eligible and/or assessed with sentinel lymph node biopsy.
Patient age group

T1/T2

SLN positivity (class
1A)

95% CI (class 1A)

SLN positivity (class
2B)

95% CI (class 2B)

All

326

⬍55

128

p-value

6.2% (14/226)

3.4–10.2%

8.3% (2/24)

1.0–27%

0.66

8.9% (8/90)

3.9–16.8%

0% (0/5)

0–52%

⬎0.99

Cohort 1

55–64

78

8.8% (5/57)

2.9–19.3%

25% (1/4)

1.0–81%

0.35

≥65

120

1.3% (1/79)

0–6.9%

6.7% (1/15)

0–32%

0.30

All

512

6.3% (22/349)

4–9.4%

24.5% (13/53)

13.8–38.3%

⬍0.001

⬍55

174

10.5% (14/133)

5.9–17%

30% (6/20)

11.9–54.3%

0.027

55–64

111

5.8% (4/69)

1.6–14.2%

37.5% (3/8)

8.5–75.5%

0.022

≥65

227

2.7% (4/147)

0.7–6.8%

16% (4/25)

4.5–36.1%

0.017

Cohort 2

Combined cohorts 1 and 2
All

838

6.3% (36/575)

4.4–8.6%

19.5% (15/77)

11.3–30.1%

⬍0.001

⬍55

302

9.9% (22/223)

6.3–14.6%

24% (6/25)

9.4–45.1%

0.046

55–64

189

7.1% (9/126)

3.3–13.1%

33.3% (4/12)

9.9–65.1%

0.016

≥65

347

2.2% (5/226)

0.7–5.1%

12.5% (5/40)

4.2–26.8%

0.009

Data in this table are also represented in Figure 1B. p-values reflect statistical significance from Fisher’s exact tests.
SLN: Sentinel lymph node.

Discussion
There is a clinical need to identify patients who are likely to have a negative SLNB result in order to reduce surgical
burden and cost. Most guidelines suggest considering SLNB for melanomas with pathologic stage T1b and above,
as well as T1a melanomas with high-risk features. However, this threshold is not absolute, and physicians weigh
many factors, including patient preference, to make decisions pursing SLNB, thus not all eligible patients undergo
the procedure [33,34]. Additional information on risk of SLN positivity and clinical outcomes could help in SLNB
decision-making.
The association of a 31-GEP class 1 signature with lower SLN positive rates was previously reported by Huang
et al. and observed in other cohorts [26,27,29]. This suggested that this test could provide information relevant to
the likelihood of a tumor to metastasize to the SLN, in addition to the previously demonstrated association of
this signature with melanoma recurrence, distant metastasis and death [24–28]. We used modeling in a retrospective
cohort of melanoma patients to identify cut-offs for clinicopathologic features that could help identify a patient
population in which the test could achieve the goal of identifying patients with <5% SLN positivity. This analysis
showed that in patients with Breslow thickness ≤2.0 mm (T1–T2) and ≥55 years of age, the current clinical
31-GEP test could achieve this goal. To validate this approach, two contemporary, multicenter study cohorts
totaling 1421 prospectively and consecutively tested patients, representative of the general population of melanoma
patients who are considered for SLNB [4,15,35], were used. It is important to note that these cohorts include T1a
patients, as a subset of this group is currently eligible and contribute to a substantial number of T1–T2 patients
who undergo the procedure [6]. Analysis of SEER data (2017 release with AJCC 8th edition staging applied) show
that 6.7% of T1a patients do undergo a SLNB procedure and since T1a constitutes the largest group of melanoma
patients (55.5% in SEER data), these represent 22.2% of SLNBs in T1–T2 patients [3]. Similar numbers have been
reported by Stiegel et al., who showed that at the Cleveland Clinic, T1a tumors accounted for 21.3% of all SLNB
procedures and 30% of SLNBs in T1–T2 patients [36].
We investigated whether the 31-GEP test could help identify a patient population that has a <5% SLN positive
rate and, based on current guideline thresholds, inform decisions on whether to perform the SLNB procedure. The
results showed that patients ≥55 years who had a class 1A GEP in a T1–T2 tumor had a 2.8% SLN positive rate,
below the 5% cut-off for recommending the procedure [6]. SEER data indicate that patients who are ≥55 years
with T1–T2 melanoma account for approximately 49% of those who are eligible for SLNB [3], therefore the results
of this study have implications for a large number of patients and could help reduce overutilization of healthcare
resources for those unlikely to have a positive SLNB. Patients in the Medicare population (≥65) with a class 1A,
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5-year survival rates

Clinical T1/T2 melanoma (age ≥55)

Class 1A

31-GEP
test

Class
1B/2A

Class 2B

MSS

OS

DMFS

RFS

99.3%
(97.8–100)

96.3%
(93.2–99.5)

93.4%
(89.4–97.7)

91.4%
(86.8–96.2)

SLN neg

94.3%
(86.9–100)

94.3%
(86.9–100)

82.9%
(71.3–96.3)

77.1%
(64.4–92.4)

SLN pos

83.1%
(64.1–100)
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99.6%
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(92.8–97.8)

93.5%
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(12.8–66.2)

32.4%
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25.6%
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Figure 2. Survival rates according to gene expression profile subclass and sentinel lymph node status for the subset of cases ≥55 years
old with T1 or T2 primary tumor thickness in a retrospective patient cohort. (A) Flow chart depicting SLN prediction with the gene
expression profile test and outcomes for patients ≥55 years old with a T1 or T2 tumor (n = 224) within a retrospective patient cohort
(n = 690). (B) Flow chart depicting SLN prediction algorithm and outcomes for T1 or T2 patients (n = 403) within a retrospective patient
cohort (n = 690). In both panels, patients with class 1A results would avoid SLNB, whereas class 1B, 2A or 2B would have the surgical
procedure. Five-year MSS, OS, DMFS and RFS rates with 95% CIs are shown for each group. SLN status for class 1B–2B patients reflects
pathological node status wherein SLNB was performed, whereas outcomes for class 1A patients are reported regardless of SLNB.
DMFS: Distant metastasis-free survival; GEP: Gene expression profile; MSS: Melanoma-specific survival; OS: Overall survival; RFS:
Recurrence-free survival; SLN: Sentinel lymph node; SLNB: Sentinel lymph node biopsy.

T1–T2 tumor had an even lower rate of SLN positivity (1.6%; i.e., well within the NCCN “Do Not Recommend”
category). Of note, patients 55–64 years of age with class 1A, T1–T2 tumors had a SLN positivity rate of 4.9%,
which approaches but is below the rate for recommending a discussion about the SLN procedure. This information
could be also useful in discussions with patients in this age group.
Older patients account for a substantial proportion of CM incidence, and 60% of melanoma-related deaths
occur in patients ≥ 65 years old. While older age is associated with a poorer prognosis, increasing age appears to be
inversely associated with SLN positivity [14,16,17,37,38], which indicates that the prognostic value of SLNB is limited
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in this population [39,40]. Our results show that patients with class 1A, T1–T2 tumors who are ≥65 years of age
have an SLN positivity rate of 1.6%, substantially lower than the threshold recommended by practice guidelines. In
the retrospective cohort, patients with a T1–T2 tumor and a class 1A GEP result had excellent MSS, OS, DMFS
and RFS rates, suggesting they could safely forgo a SLNB procedure. This information could be helpful in making
decisions about the SLNB in a population with a higher frequency of comorbidities and for which the procedure
already shows a lower yield.
Survival rates for class 1, T1/T2 patients in the retrospective cohort support this approach, with MSS rates
comparable to those observed in patients with T1a tumors for whom current guidelines do not recommend SLNB [2].
MSLT-I showed that observation versus planned SLNB does not affect MSS [4], while MSLT-II demonstrated that
a delay in completion lymph node dissection does not adversely impact survival [7]. Based on these data, one
would expect that clinical follow-up of class 1A patients, with low-intensity follow-up recommendations for
the identification of secondary skin cancers and recurrences and lymphadenectomy for those few who develop
clinically detectable nodal disease, should achieve similar outcomes to those who currently undergo a planned
SLNB. However, it is important to stress that follow-up for this low-risk group should be done according to
current management guidelines and taking into account the patient’s probability of recurrence (per NCCN
recommendations) [6]. Patients for whom the decision is made to forgo SLNB should still have follow-up that
includes clinical examination of the lymph node basin to ensure that, although infrequent, nodal metastases are
identified as early as possible.
Limitations
Limitations of this study include the fact that long-term follow up is not available for patients in the prospective
cohorts, however outcomes were modeled in the retrospective cohorts which have long-term outcomes [32]. Another
potential limitation is that the study did not include a significant number of T1b–T2 patients who might have been
considered for SLNB, but who either decided not to undergo the procedure or the procedure was not performed
due to medical contraindications. As with all innovative approaches, replication in additional patient cohorts is
recommended, to confirm the validity of this approach. Thus, a second multi-center validation study is ongoing to
evaluate patients with T1–T2 melanoma who were clinically tested with the 31-GEP test and their SLNB results.
Additionally, prospective, multi-center studies to track and evaluate clinical outcomes of patients for whom the
31-GEP test is used to guide SLNB decisions under IRB-approved protocols are planned. Based on results of the
MSLT-I trial it is expected that class 1A patients with T1–T2 tumors who forgo the SLNB procedure will not
demonstrate a significant difference in melanoma-specific survival rates compared with those who are managed
with SLNB [4].
Conclusion
Incorporation of molecular signatures to guide biopsy recommendations is now routine for patients with thyroid,
prostate and lung cancers [41–43]. Our results show that a gene expression signature can be applied in melanoma to
identify a patient population with <5% predicted probability of a positive SLN with demonstrated high survival
rates and therefore has potential utility in guiding SLNB decisions. Additional multi-center retrospective and
prospective studies to confirm and expand these results are ongoing or planned. If used in this way, the 31-GEP test
could potentially reduce a substantial proportion of SLNBs while still maintaining a robust survival rate in those
patients with low-risk tumor biology. These patients could benefit from avoidance of risks associated with surgery
and anesthesia. Sentinel lymph node guidance using the GEP test is not meant to deter patients from surgical
consultation, as it is always important to discuss all risks/benefits in an individual clinical situation. Rather, this test
may serve as an additional decision-making tool for adhering to national recommendations of personalized care.
Future perspective
Over the next 5 to 10 years we expect that prognostication in melanoma will continue to evolve and incorporate
molecular features of the tumor with traditional clinicopathologic features in order to best estimate individual risk,
a strategy that has proven successful in other cancers. This is critical to defining informed clinical care strategies that
benefit patients. With further delineation of risk profiles and continued therapeutic advances in the adjuvant and
metastatic settings, melanoma patient care paradigms will continue to shift, particularly regarding the utilization of
surgical intervention such as with completion lymph node dissection. Determination of the risk of SLN positivity
is an example for which additional objective information is warranted. Given the reported rates of SLN positivity
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that range from 5–12% in T1 (≤1 mm) melanomas, and 15–20% in tumors of intermediate thickness, there will
clearly be a clinical benefit to focus the SLNB surgical procedure in the group that is most likely to benefit from
it. We expect that the incorporation of gene expression profiling information for better delineation of those who
have lower and higher risks of SLN positivity will have a substantial impact on clinical decision-making in the
years ahead. We expect that this paradigm shift will lead to improved patient care while facilitating efficient and
appropriate use of healthcare resources.
Summary points
• National guidelines recommend a threshold of 5% positivity risk for considering sentinel lymph node (SLN) biopsy.
• Most patients have a negative SLN result, including older patients who have poorer prognoses despite lower SLN
positivity.
• There is a clinical need to identify patients who are likely to have a negative SLN biopsy result in order to reduce
surgical burden and cost.
• A validated 31-gene expression profile (31-GEP) test for prognostication estimates metastatic risk as low (class 1A)
or high (class 2B).
• This study evaluated whether the 31-GEP test could identify patients who have a low risk of SLN positivity and
favorable outcomes, and thus could safely avoid SLN biopsy.
• In a validation cohort of 1421 prospectively-tested patients, patients 55–64 and ≥65 years with T1–T2 melanoma
and class 1A results had SLN positivity rates of 4.9 and 1.6%.
• In a retrospective cohort of 690 patients, patients ≥55 years with T1–T2 melanoma and class 1A results had
favorable recurrence-free, distant metastasis-free, overall and melanoma-specific survival rates.
• The 31-GEP test can identify patients with T1–T2 melanoma who have both a low risk of SLN positivity and a
good prognosis, suggesting this test can help address the clinical need of identifying patients at low risk for a
positive SLN and can inform SLNB decisions.
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